Background. Pulmonary hypertension occurs in approximately 1% of the global population, and the prognosis for such patients may be poor. However, the mechanisms underlying the development of this disease remain unclear. Thus, understanding the development of pulmonary hypertension and finding new therapeutic targets and approaches are important for improved clinical outcomes. Methods. Lung tissue specimens were collected from six patients with atrial septal defect and pulmonary hypertension (all women, with a mean age of 46.5 ± 4.7 years, and their condition could not be corrected with an internal medical occlusion device) and from nine control patients with lung cancer who underwent lobectomy (six men and three women, with a mean age of 56.7 ± 1.7 years). Isobaric tags for relative and absolute quantitation and liquid chromatography tandem mass spectrometry analyses were used to detect protein expression levels. Results. We found 74 significantly upregulated and 88 significantly downregulated differentially expressed proteins between control and pulmonary hypertensive lung tissue specimens. Gene ontology analyses identified the top 20 terms in all three categories, that is, biological process, cellular component, and molecular function. Kyoto Encyclopedia of Genes and Genomes and protein-protein interaction analyses determined the top 10 signaling pathways and found that the six hub proteins associated with the differentially expressed upregulated proteins (PRKAA1, DHPR, ACTB, desmin, ACTG1, and ITGA1) were all involved in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy. Conclusion. Our results identified protein expression profile changes in lung tissue derived from patients with pulmonary hypertension, providing potential new biomarkers for clinical diagnosis and prognosis for patients with pulmonary hypertension and offering candidate protein targets for future therapeutic drug development. Abstract 24 Background. Pulmonary hypertension occurs in approximately 1% of the global population, and 25 the prognosis for such patients may be poor. However, the mechanisms underlying the 26 development of this disease remain unclear. Thus, understanding the development of pulmonary 27 hypertension and finding new therapeutic targets and approaches are important for improved 28 clinical outcomes.
81 Therefore, it is important to find new and effective targets to treat pulmonary hypertension. 82 83 Isobaric tags for relative and absolute quantitation (iTRAQ) in combination with liquid 84 chromatography tandem mass spectrometry (LC-MS/MS) are powerful tools for identifying 85 protein expression levels of the various types of proteins that are in a specimen. In the present 86 study, we obtained pulmonary tissue specimens from patients undergoing surgical pulmonary 87 procedures and used the iTRAQ and LC-MS/MS methods to identify proteins that were 88 differentially expressed in the pulmonary tissue of patients with pulmonary hypertension versus 89 those from patients without this disease. Using bioinformatics analysis, we assessed those 90 differentially expressed proteins (DEPs) to determine potential key proteins and their related 91 signaling pathways that may be associated with the development of pulmonary hypertension. 
Specimen collection and patient characteristics
170 From April to September 2016, we collected lung tissue specimens from six patients with atrial 171 septal defect and pulmonary hypertension. The patients were all women, with a mean (SD) age 172 of 46.5 ± 4.7 years, and their condition could not be corrected with an internal medical occlusion 173 device. For the control group, nine patients with lung cancer who underwent lobectomy were 174 enrolled: six men and three women, with a mean (SD) age of 56.7 ± 1.7 years. Among the 175 patients with pulmonary hypertension, the mean pulmonary systolic pressure was 66.7 ± 5.5 176 mmHg; mean pulmonary artery diastolic pressure, 23.2 ± 1.6 mmHg; mean pulmonary artery 177 pressure, 39.7 ± 3.4 mmHg; mean pulmonary artery resistance, 3.27 ± 0.28 Wood units; 178 pulmonary oxygen saturation, 87.3% ± 0.84%; and mean patient body surface, 1.52 ± 0.06 m 2 .
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